Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Mazen Noureddin?

Mazen Noureddin

Director Fatty Liver Program

Medical Group Of Beverly Hills Inc

HQ Phone:  (310) 247-4651

Direct Phone: (310) ***-****direct phone

Email: m***@***.org

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Medical Group Of Beverly Hills Inc

STE 606, 250 N ROBERTSON BLVD

Beverly Hills, California,90211

United States

Find other employees at this company (6,307)

Background Information

Employment History

Daily Trojan


Director of Fatty Liver Program

Cedars-Sinai Medical Center


Affiliations

OWL Metabolomics

Scientific Advisory Board Member


Education

MD


Web References(3 Total References)


www.owlmetabolomics.com

Mazen Noureddin, MD Director of Fatty Liver Program at Cedars-Sinai Medical Center


www.owlmetabolomics.com

OWL > Management team > Mazen Noureddin, MD
OWL Mazen Noureddin, MD Mazen Noureddin, MD, is the Director of Fatty Liver Program at Cedars-Sinai Medical Center with a focus on translational research, particularly in nonalcoholic fatty liver disease (NAFLD). Dr. Noureddin has conducted investigational, translational and clinical studies of novel treatments for nonalcoholic steatohepatitis (NASH). One the pathogenesis pathways that he is currently investigating is the role of S-adenosylmethionine (SAMe) in NAFLD/NASH. Dr. Noureddin began working on hepatic SAMe during his internal medicine residency at the University of Southern California (USC) in the laboratory of Shelly Lu, MD. After his NIH fellowship, Dr. Noureddin embarked on a two-year gastroenterology fellowship at the University of California, San Diego, where he focused on NAFLD and NASH and assessing the clinical utility of a new liver-imaging technique, MRI-proton density fat fraction (MRI-PDFF). This scanning methodology is currently considered the new reference standard for the imaging of fatty liver in NAFLD patients. Dr. Noureddin returned to the University of Southern California (USC) and established their fatty liver program to continue research on NAFLD/NASH, while conducting translational research and clinical trials. Subsequently, Dr. Noureddin teamed up with Cedars-Sinai in 2015 to establish the Cedars-Sinai Fatty Liver Program. He is currently active in a number of clinical studies investigating new drug treatments for NASH, researching the translational pathogenesis of NAFLD/NASH and is involved in novel liver biomarker research & development.


www.owlmetabolomics.com

· Mazen Noureddin, MD, is the Director of Fatty Liver Program at Cedars-Sinai Medical Center with a focus on translational research, particularly in nonalcoholic fatty liver disease (NAFLD).
Dr. Noureddin has conducted investigational, translational and clinical studies of novel treatments for nonalcoholic steatohepatitis (NASH) and helped to validate a new liver-imaging technique, MRI-proton density fat fraction (MRI-PDFF). Dr. Noureddin completed his hepatology fellowship at the National Institutes of Health (NIH) and is presently active in a number of clinical studies investigating new drug treatments for NASH, researching the translational pathogenesis of NAFLD/NASH and is deeply enganged in novel liver biomarker R&D.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory